Stock DRNA DICERNA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Dicerna Pharmaceuticals, Inc.

Equities

DRNA

US2530311081

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition
MT
Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk
MT
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Global BMI Index
CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P TMI Index
CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Biotechnology Select Industry Index
CI
Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
Dicerna Pharmaceuticals : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition - Form 8-K
PU
DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Composite Index
CI
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of remaining 97% stake in Dicerna Pharmaceuticals, Inc..
CI
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
BU
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Biotechnology Index
CI
Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acquisition by Novo Nordisk, Adjusts PT to $38.25 From $28
MT
Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $38.25 From $28 on Pending Acquisition
MT
Insider Sell: Dicerna Pharmaceuticals
MT
Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38 From $35
MT
Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144
MT
North American Morning Briefing : Stock Futures -3-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRNA Stock
  4. News Dicerna Pharmaceuticals, Inc.